Novo Nordisk reports SOUL trial results showing reduced cardiovascular risk with oral semaglutide in… EP News Bureau Apr 8, 2025 Phase 3b trial data presented at ACC and published in NEJM highlights cardiovascular outcomes of oral semaglutide in patients with…
Linagliptin demonstrates cardiovascular and renal safety in Asian adults with type 2 diabetes EP News Bureau Jun 30, 2020 In a sub-analysis of the CAROLINA cardiovascular outcome trial, linagliptin demonstrated no increased cardiovascular risk versus…
